

Kimberly J Bussey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7660796/publications.pdf>

Version: 2024-02-01

54
papers

4,718
citations

201674

27
h-index

254184

43
g-index

56
all docs

56
docs citations

56
times ranked

7193
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer progression as a sequence of atavistic reversions. <i>BioEssays</i> , 2021, 43, e2000305.	2.5	37
2	Reverting to single-cell biology: The predictions of the atavism theory of cancer. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 165, 49-55.	2.9	12
3	MYBPC3 Haplotype Linked to Hypertrophic Cardiomyopathy in Rhesus Macaques (<i>Macaca mulatta</i>). <i>Comparative Medicine</i> , 2020, 70, 358-367.	1.0	0
4	Abstract 3381: Determining the relationship between a measure of stress-induced mutagenesis and patient survival in cancer. , 2018, , .		0
5	A platform for high-throughput bioenergy production phenotype characterization in single cells. <i>Scientific Reports</i> , 2017, 7, 45399.	3.3	12
6	Ancestral gene regulatory networks drive cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 6160-6162.	7.1	46
7	Ancient genes establish stress-induced mutation as a hallmark of cancer. <i>PLoS ONE</i> , 2017, 12, e0176258.	2.5	33
8	Abstract 507: A signature of stress-induced mutagenesis in cancer. , 2017, , .		0
9	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016, 29, 723-736.	16.8	482
10	Transcriptional regulation by normal epithelium of premalignant to malignant progression in Barrett's esophagus. <i>Scientific Reports</i> , 2016, 6, 35227.	3.3	3
11	Vorinostat differentially alters 3D nuclear structure of cancer and non-cancerous esophageal cells. <i>Scientific Reports</i> , 2016, 6, 30593.	3.3	3
12	Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma. <i>Clinical and Translational Medicine</i> , 2016, 5, 1.	4.0	28
13	Pathway Implications of Aberrant Global Methylation in Adrenocortical Cancer. <i>PLoS ONE</i> , 2016, 11, e0150629.	2.5	35
14	Ancient hot and cold genes and chemotherapy resistance emergence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10467-10472.	7.1	41
15	Abstract 4033: Suppressive role of normal epithelium in pre-malignant to malignant progression of Barrett's esophagus. , 2015, , .		0
16	ZNF367 Inhibits Cancer Progression and Is Targeted by miR-195. <i>PLoS ONE</i> , 2014, 9, e101423.	2.5	36
17	Detection of an ATRT Brain Tumor Gene Deletion Diagnostic in Circulating Blood using Next Gen Sequencing. <i>Cancer Genetics</i> , 2014, 207, 450.	0.4	1
18	Detection of an Atypical Teratoid Rhabdoid Brain Tumor Gene Deletion in Circulating Blood Using Next-Generation Sequencing. <i>Journal of Child Neurology</i> , 2014, 29, NP81-NP85.	1.4	10

#	ARTICLE	IF	CITATIONS
19	Whole-genome Sequencing of an Aggressive BRAF Wild-type Papillary Thyroid Cancer Identified EML4-ALK Translocation as a Therapeutic Target. <i>World Journal of Surgery</i> , 2014, 38, 1296-1305.	1.6	54
20	Abstract 4297: Quantifying three-dimensional cellular morphology and its heterogeneity in epithelial cancers by single-cell optical tomography. , 2014, , .		0
21	PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target. <i>Surgery</i> , 2013, 154, 1405-1416.	1.9	73
22	Abstract 1781: Whole-genome and RNA sequencing identify a novel recurrent translocation in adrenocortical carcinoma. , 2013, , .		0
23	Abstract B10: Vorinostat exposure results in decreased lamin B1 expression and nuclear structure normalization in an in vitro model of esophageal adenocarcinoma progression. , 2013, , .		0
24	A fly in the ointment: reassessing mitotane's role in the treatment of adrenocortical carcinoma. <i>Pharmacogenomics</i> , 2012, 13, 1207-1209.	1.3	3
25	Preclinical Investigation of Nanoparticle Albumin-Bound Paclitaxel as a Potential Treatment for Adrenocortical Cancer. <i>Annals of Surgery</i> , 2012, 255, 140-146.	4.2	17
26	Isotropic 3D Nuclear Morphometry of Normal, Fibrocystic and Malignant Breast Epithelial Cells Reveals New Structural Alterations. <i>PLoS ONE</i> , 2012, 7, e29230.	2.5	57
27	Abstract 978: Inhibition of Polo-like kinase 1 as a strategy in the treatment of adrenocortical carcinoma. , 2012, , .		1
28	Abstract 4057: Quantitative assessment of 3D nuclear architecture in colon epithelial cells by micro-optical computed tomography. , 2012, , .		0
29	Abstract 5668: Vorinostat exposure results in differential sensitivity and nuclear structure normalization in an in vitro model of esophageal adenocarcinoma progression. , 2012, , .		0
30	Toward a pathway-centered approach for the treatment of adrenocortical carcinoma. <i>Current Opinion in Oncology</i> , 2011, 23, 34-44.	2.4	5
31	Targeted Therapies for Adrenocortical Carcinoma: IGF and Beyond. <i>Hormones and Cancer</i> , 2011, 2, 385-392.	4.9	20
32	Genomic signatures of cancer: Basis for individualized risk assessment, selective staging and therapy. <i>Journal of Surgical Oncology</i> , 2011, 103, 563-573.	1.7	32
33	Abstract LB-264: Whole genome sequencing of an adrenocortical carcinoma reveals a pathogenic context and exposes therapeutic options. , 2011, , .		0
34	Multi-Institutional Tumor Banking. <i>Pancreas</i> , 2010, 39, 949-954.	1.1	7
35	Multifactorial Regulation of E-Cadherin Expression: An Integrative Study. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1-16.	4.1	49
36	Abstract 3672: Adrenocortical carcinoma cell lines are sensitive to compounds targeting the G2/M transition. , 2010, , .		1

#	ARTICLE	IF	CITATIONS
37	Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment. <i>Future Oncology</i> , 2009, 5, 641-655.	2.4	18
38	Adrenocortical Cancer. <i>Surgical Clinics of North America</i> , 2009, 89, 1255-1267.	1.5	38
39	Asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2613-2623.	4.1	97
40	Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 853-867.	4.1	157
41	Karyotypic "state" as a potential determinant for anticancer drug discovery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2964-2969.	7.1	25
42	Membrane Transporters and Channels. <i>Cancer Research</i> , 2004, 64, 4294-4301.	0.9	281
43	Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. <i>BMC Bioinformatics</i> , 2004, 5, 80.	2.6	95
44	Predicting drug sensitivity and resistance. <i>Cancer Cell</i> , 2004, 6, 129-137.	16.8	496
45	Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. <i>Genome Biology</i> , 2003, 4, R82.	9.6	91
46	MatchMiner: a tool for batch navigation among gene and gene product identifiers. <i>Genome Biology</i> , 2003, 4, R27.	9.6	135
47	GoMiner: a resource for biological interpretation of genomic and proteomic data. <i>Genome Biology</i> , 2003, 4, R28.	9.6	1,038
48	Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 14229-14234.	7.1	463
49	Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. <i>Cancer Research</i> , 2003, 63, 5243-50.	0.9	144
50	Karyotypic complexity of the NCI-60 drug-screening panel. <i>Cancer Research</i> , 2003, 63, 8634-47.	0.9	227
51	SNRPN methylation patterns in germ cell tumors as a reflection of primordial germ cell development. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 342-352.	2.8	51
52	Chromosomes 1 and 12 abnormalities in pediatric germ cell tumors by interphase fluorescence in situ hybridization. <i>Cancer Genetics and Cytogenetics</i> , 2001, 125, 112-118.	1.0	28
53	Chromosome abnormalities of eighty-one pediatric germ cell tumors: Sex-, age-, site-, and histopathology-related differences? a Children's Cancer Group study. <i>Genes Chromosomes and Cancer</i> , 1999, 25, 134-146.	2.8	136
54	Chromosome abnormalities of eighty-one pediatric germ cell tumors: Sex-, age-, site-, and histopathology-related differences? a Children's Cancer Group study. <i>Genes Chromosomes and Cancer</i> , 1999, 25, 134-146.	2.8	1